XML 71 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2020
Mar. 31, 2020
Aug. 31, 2018
May 31, 2018
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2016
Other Commitments [Line Items]                      
Gain (loss) on strategic investment             $ 2,329,000 $ (997,000) $ 997,000    
Restricted cash             5,770,000 5,770,000 4,787,000    
Corporate Credit Card Program | Letter of Credit                      
Other Commitments [Line Items]                      
Restricted cash                     $ 2,000,000.0
Fleet Program | Letter of Credit                      
Other Commitments [Line Items]                      
Restricted cash             400,000        
Other assets                      
Other Commitments [Line Items]                      
Aggregate carrying amount of strategic equity investment             3,600,000 1,300,000      
Other expense                      
Other Commitments [Line Items]                      
Gain (loss) on strategic investment             2,300   1,000,000.0    
Cersci Therapeutics                      
Other Commitments [Line Items]                      
Upfront consideration and transaction costs $ 52,800,000                    
Upfront payment $ 44,300,000                    
Upfront payment conditions The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.                    
Common stock issuance 1,200,000                    
Cersci Therapeutics | Research and development                      
Other Commitments [Line Items]                      
Assets acquisition and upfront payment         $ 45,700,000            
License Agreements                      
Other Commitments [Line Items]                      
Upfront payment             11,000,000.0 $ 72,700,000 $ 1,400,000    
Mile stone payments payable     $ 10,000,000.0                
Milestone payment may be due             $ 10,000,000.0        
License Agreements | North America                      
Other Commitments [Line Items]                      
Mile stone payments payable     40,000,000.0                
License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Upfront payment   $ 10,000,000.0                  
Upfront license fee     10,000,000.0                
License Agreements | Neuren | Research and development | North America                      
Other Commitments [Line Items]                      
Upfront payment           $ 10,000,000.0       $ 10,000,000.0  
Exclusivity Deed | Neuren                      
Other Commitments [Line Items]                      
Aggregate carrying amount of strategic equity investment       $ 3,100,000              
Shares subscribed       1,330,000              
Exclusivity Deed | Neuren | Sales, general and administrative                      
Other Commitments [Line Items]                      
Payments for exclusive right       $ 900,000              
Maximum                      
Other Commitments [Line Items]                      
Percentage of royalty payments obligation on net product sales             2.00%        
Mile stone payments payable             $ 2,200,000,000        
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones                      
Other Commitments [Line Items]                      
Compensation expense related to mergers to former holders $ 887,000,000.0                    
Maximum | License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Mile stone payments payable   $ 515,000,000.0 $ 455,000,000.0     $ 515,000,000.0